ADD
7
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein
Technology-Enhanced Executive Functioning Intervention for ADHD
Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet